Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.
J Pediatric Infect Dis Soc
; 11(7): 337-340, 2022 Jul 21.
Article
em En
| MEDLINE
| ID: mdl-35472147
ABSTRACT
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Quinazolinas
/
Infecções por Citomegalovirus
/
Transplante de Células-Tronco Hematopoéticas
/
Acetatos
Limite:
Adolescent
/
Humans
Idioma:
En
Revista:
J Pediatric Infect Dis Soc
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos